The global Magnetic Resonance Imaging (MRI) Contrast Agents Market recorded sales worth USD 871.0 Million in the year 2021. The market is expected to grow 1.3X over the forecast period 2022 to 2029. The industry will record sales worth USD 1.23 Billion by the end of 2029.
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 910.9 Million |
| Market Value 2029 | USD 1.23 Billion |
| CAGR 2022 to 2029 | 4.4% |
| Share of top 5 countries | 60.8% |
| Key Players | The key players of the magnetic resonance imaging (MRI) contrast agents market are Bayer AG, GE Healthcare, LLC, Guerbet GmbH, Bracco Imaging SpA, and Miltenyi Biotec B.V. & Co. Kg. |
In 2021, the magnetic resonance imaging (MRI) contrast agents market accounted for around 17.8% revenue share of the global contrast agents market revenue which was recorded to be around USD 4.9 Billion. MRI scans have become one of the most commonly used diagnostic tools to ascertain the presence of tumours, clots, aneurysms, vessel structure issues and much more. The high adoption rate of this scanning technique is a key factor attributing to the expansion of this market globally.
The contrast agents or dyes when injected into the body before an MRI scan improve the quality of the images by increasing the contrast between normal and diseased tissues in the body. Paramagnetic contrast agents, which are gadolinium ion-based contrast agents are most commonly used to visualize the internal body tissues for diagnostic purposes.
The global MRI contrast agents market is expected to grow at a steady pace over the forecast period (2022 to 2029) due to the growing preference for imaging technology for disease diagnosis and the increasing number of MRI scanner installations around the world. According to the data published by the Organization of Economic Co-operation and Development (OECD), Japan had the highest density of MRI scanner installation in the year 2019 with 55 MRI scanning units per million populations in the country.
The Healthcare sector across the globe is going through a paradigm shift and is focusing on value-based models for offering better care to the consumers, all the regulatory authorities around the world are assisting in this development by making the product approval process easier for this industry.
Non-invasive treatment methodology and multimodal diagnostic imaging services are experiencing a high adoption rate over the past few years which is seen to positively impact the growth of the global magnetic resonance imaging (MRI) contrast agents market.
Paramagnetic contrast agents accounted for more than 99% market share, by the value of the total magnetic resonance imaging (MRI) contrast agents market in the year 2021 with the recorded sales worth USD 863.8 Million in the same year. The increasing burden of non-communicable diseases around the world is a key factor driving the sales of the global magnetic resonance imaging (MRI) contrast agents market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 4.44% |
| H1, 2022 Projected | 4.41% |
| H1, 2022 Outlook | 4.31% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 10 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 13 ↓ |
FMI provides a comparative analysis of the growth rate of the market and developmental prospects in the global magnetic resonance imaging (MRI) contrast agents market. The market growth is influenced by government financial support and growing approvals for contrast agents in accordance with the impact of macro and industry factors.
The key developments in this market include technological advancements in diagnostic imaging and new product launches by market players.
According to Future Market Insight analysis, the magnetic resonance imaging (MRI) contrast agents market is estimated to drop by 10 BPS in H1-2022 - outlook over H1, 2022 projected period. Furthermore, the market will show a drop in BPS change with 13 Basis Point Share (BPS) in H1-2022 (O) compared to H1, 2021.
The major factors for this drop in BPS are attributed to lower utilization of routine testing during COVID-19, and also because people tend to prefer the alternative cost-effective options. The extracellular fluid (ECF) agent segment is expected to perform fairly and attain promising growth prospects in the next half of the projection period.
However, there are some points that will lead the market ahead in the industry, including machine-learning-based image analysis procedures, which will provide lucrative opportunities to improve image contrast in MRI. Also, key players are strategically planning to expand the market reach through collaborations and mergers.
According to Future Market Insights (FMI), the demand for magnetic resonance imaging (MRI) contrast agents during the period of 2014 to 2021 expanded at a CAGR of 4.1%. Growing patient awareness regarding non-invasive diagnostic techniques and their accessibility to healthcare were some of the key reasons for the growth of this market in the past few years.
The number of MRI scans has been continuously increasing due to the growing prevalence of chronic diseases affecting brains, spines and livers and incidences of injuries in joints such as the back and knee. Data published by Organization for Economic Co-operation and Development (OECD), depicts that the number of MRI scans performed in the United States per 1000 population was highest in the world in 2018. The growth of MRI scans performed in the USA was increased by about 1.08% that is 109.5 per 1000 population in 2014 to 118.9 per 1000 population in 2018.
The demand for MRI contrast agents has significantly increased in the past few decades because of the rapid procedural advancement in medical imaging technology MRI. To meet the patients’ needs undergoing diagnostic procedures, the key market leaders are now focusing on large scale investments towards uninterrupted and sustainable product supply of contrast agents.
For instance, GE Healthcare invested over 65 million USD in its worldwide supply network between 2013 and 2016, to increase its manufacturing capacity. The company provides service and supplies contrast media to radiologists across all medical and technical aspects of imaging. GE Healthcare reported that its contrast agents are used in above 70 million procedures per year.
Multimodality imaging takes advantage of different combination imaging modalities in medical imaging to provide a more complete anatomy picture under investigation. MRI is widely used in both therapeutic and diagnostic applications due to its multi-planner imaging capability, sensitivity to subtle changes in soft tissue function and morphology and high signal to noise ratio.
Molecular imaging devices are usually integrated with CT (computed tomography) and MRI scanners to correlate the anatomical location with biological processes in the body. Computers are used to fuse anatomical images and biological processes to help clinicians make better therapeutic and diagnostic decisions. Wider the applications of the scanner, more is the adoption of the product.
COVID-19 pandemic harmed the MRI contrast agents market because the pandemic reduced patient footfall to the hospitals and diagnostic centres due to the infection scare. Reduced patient volume affected the market negatively in the year 2020.
The magnetic resonance imaging (MRI) contrast agents market key players are focusing on getting various regulatory agencies approvals for expanding their product portfolio of MRI contrast agents around the world.
For instance, Bayer AG in July 2019, announced the FDA approval of their Gadavist®, which is a gadobutrol injection, one of its kind contrast agent for cardiac MRI for the detection and monitoring of coronary artery disease.
In November 2019, GE Healthcare announced the FDA approval of their MRI contrast agent Clariscan™, which is a gadolinium-based, macrocyclic, ionic. This contrast agent is used to visualize the disruption of the blood-brain barrier or any abnormal vascularity in both adult and paediatric patients.
The same contrast agent, Clariscan™ was launched by GE Healthcare in the 2017 meeting of the European Congress of Radiology.
The magnetic resonance imaging (MRI) contrast agents market is consolidated with a few key players such as Bayer AG, GE Healthcare, LLC, Guerbet GmbH, Bracco Imaging SpA, and Miltenyi Biotec B.V. & Co. Kg.
Future Market Insights expects the global magnetic resonance imaging (MRI) contrast agents market to expand at the cumulative CAGR of 4.4% over the forecast period (2022 to 2029) since many of the key players are focusing their efforts to expand their businesses around the world.
Principal Consultant
MRI contrast agents are increasingly being used in the diagnosis of chronic diseases using MRI technology. According to WHO, chronic diseases will account for three-quarters of global deaths by 2020. Chronic diseases can be preventable if patients are diagnosed at an early stage.
However, up until now, only four to five companies such as Bayer AG, GE Healthcare LLC, Guerbet GmbH and Bracco Imaging SpA are actively involved in the manufacturing of MRI contrast agents globally, which will create some huge opportunities for other small as well as big manufacturers to enter the MRI contrast agents market.
Various initiatives taken by the government to develop modern healthcare centres and also provide financial support to develop new MRI machines are one of the key trends driving the magnetic resonance imaging (MRI) contrast agents market growth.
Continuous investments by the government for the treatment of cancer and chronic disorders is the key factor that provides opportunities for MRI contrast agents market players to develop and expand their sale of MRI contrast agents in emerging markets.
In March 2018, the government of India announced the development of indigenous low-cost MRI machines in the meeting of the Society for Applied Microwave Electronics Engineering & Research (SAMEER, under the MeitY) to bring down the cost of scan for patients.
All approved contrast agents contain gadolinium - a chemical element, which is toxic in its free form. Binding agents or cheaters are used to make gadolinium safe for use in humans, to prevent the deposition of metals in the body.
However, some concerns have been raised in recent studies that not all the gadolinium injected for the scan are eliminated from the body, and some traces of gadolinium left in tissues may cause harm to the body in the long term, which is expected to restrain the market growth.
In most cases, physicians do not prefer contrast media during the MRI scan as it was found toxic and harmful to some extent. Alternative methods are cost-effective and fast as compared to the MRI contrast agent diagnosis method.
Ultrasound is a real-time method of investigation, which offers contrast-enhanced imaging with safety and cost-effective medical imaging possibly restraining the MRI contrast agents market. Also, X-ray and CT scans are good alternatives for MRI scans, which can produce nearly equivalent test results anticipated to restrain the MRI contrast agents market growth.
In developing countries, the cost of MRI diagnosis is not pocket-friendly, restricting the adoption of MRI techniques for diagnosis. Hence, this may slow down the growth of the market. MRI contrast agents are available at a reasonable cost, but the cost of an MRI scan is very high. Due to this, patients, as well as physicians, also think twice before they use MRI for disease diagnosis in developing countries.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The USA accounted for 94.4% market share, by the value of the MRI contrast agents in North America in 2021 and is expected to expand at a CAGR of 4.5% over the forecast period. According to the Centre for Disease Control and Prevention, around 18.2 million people in the USA suffered from coronary heart disease (CHD) in the year 2017. MRI contrast is one of the preferred techniques to diagnose CHD, hence the high market shares of the USA
The sales of magnetic resonance imaging (MRI) contrast agents in Germany were recorded to be USD 66.9 Million in the year 2021 and is expected to grow 1.5X by the end of 2029 with a cumulative CAGR of 5.9% over the forecast period. According to the Organization of Economic Co-operation and Development (OCED), there were around 35 MRI scanners installed per one million people in Germany in the year 2018. With the high rate of production adoption seen in Germany, the country accounts for this high share in Europe.
The sales of MRI contrast agents in India were recorded to be USD 42.5 Million in the year 2021, which accounted for 58.2% market share, by the value of the market in South Asia. Increasing government initiatives to offer low-cost MRI scanning to the consumers in India are contributing to the high product adoption rate in India. According to an article published by the Tata School of Social Studies, over 9.2 lakh MRI scans were performed in Chennai alone, in the year 2019, which was because the state government slashed the price to half in the same year.
China accounted for approximately half of the total MRI contrast agents market in East Asia in the year 2021. The Chinese market for these contrast agents is expected to expand at a CAGR of 6.4% over the forecast year with the estimated sales of USD 88.5 Million by the end of 2029. Since China is a key raw material provider for the manufacturers of MRI contrast agents around the world, it is attributed to the high market share in the East Asian market.
The magnetic resonance imaging (MRI) contrast agents market recorded sales worth USD 871.0 Million in the year 2021 and the market is expected to expand 1.35X by the end of 2029. The industry is anticipated to grow at a CAGR of 4.4% over the forecast period due to the increasing demand for precise and cost-effective diagnostic techniques around the world.
Paramagnetic contrast agents are of three types viz. extracellular fluid (ECF) agents, organ-specific agents and blood pool contrast agents (BPCAs). The extracellular fluid contrast agents are the most commonly used paramagnetic contrast agents as they have a variety of applications in the diagnosis of diseases related to head and neck, blood vessels, blood-brain barrier, bone tissue examinations and much more.
Due to the aforementioned reasons, the paramagnetic contrast agents accounted for more than 99% of the total market share, by the value of the magnetic resonance imaging (MRI) contrast agents market in the year 2021 and will continue a similar trend over the forecast period.
Hospitals accounted for nearly 54% of the market share, by the value of the global MRI contrast agents’ industry in the year 2021 with sales worth USD 473.6 Million in the same year. Hospital sales are expected to expand at a CAGR of 4.4% over the forecast period. Hospitals are the go-to centres for all the patients seeking major diagnostic tests around the world. All chronic illnesses are treated in the hospitals, which explains the high market share.
The key players of this industry are working on expanding their product portfolio through strategic partnerships, acquisitions and mergers, and achieving FDA approvals.
For Instance, in November 2019, Guerbet announced a strategic partnership with InterSystems, to expand the scope of their Contrast&Care® which is a contrast media injection management solution to optimize and effectively integrate this patient data management tool in the hospitals and various imaging centres.
In August 2019, Bracco Imaging announced the acquisition of Blue Earth Diagnostics to broaden its product portfolios in precision medicine and personalized diagnostics.
In December 2020, Bracco Diagnostics Inc., which is a USA subsidiary of Bracco imaging S.p.A, announced the FDA approval of their ProHance®, which is a Gadoteridol injection, 279.3 mg/mL used intravenously for MRI scanning, in neonate patients to visualize the disruption of the blood-brain barrier or any other abnormal activities in brain and spine.
| Attributes | Details |
|---|---|
| Forecast Period | 2022 to 2029 |
| Historic Data available for | 2014 to 2021 |
| Market Analysis | USD Million for value |
| Key Countries covered | USA, Canada, Germany, UK, France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, South Africa. |
| Key Segments covered | Product Type, End-User & Country. |
| Key Companies Profiled | Bayer AG; GE Healthcare, LLC; Guerbet GmbH; Bracco Imaging SpA; Miltenyi Biotec B.V. & Co. Kg. |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization and Pricing | Available upon request |
Paramagnetic contrast agents and supermagnetic contrast agents are used in MRI contrast scans.
The magnetic resonance imaging (MRI) contrast agents market is expected to grow at a cumulative CAGR of 4.4% over the forecast period 2022 to 2029.
The magnetic resonance imaging (MRI) contrast agents market recorded sales worth USD 871.0 Million in the year 2021 and is expected to be worth USD 1.23 Billion by the end of 2029.
The key players of the magnetic resonance imaging (MRI) contrast agents market are Bayer AG, GE Healthcare, LLC, Guerbet GmbH, Bracco Imaging SpA, and Miltenyi Biotec B.V. & Co. Kg.
The paramagnetic contrast agents dominated the MRI contrast agents market with a market share as high are 99.2% in the year 2021.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Key Success Factors 5. Global Market Volume (Units) Analysis 2014 to 2021 and Forecast, 2022 to 2029 6. Global Market to Pricing Analysis 7. Global Market Value (USD) Analysis 2014 to 2021 and Forecast, 2022 to 2029 8. Market Background 9. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, By Product Type 9.1. Paramagnetic Contrast Agents 9.1.1. Extracellular Fluid (ECF) Agents 9.1.2. Blood Pool Contrast Agents (BPCAs) 9.1.3. Organ to Specific Agents 9.2. Superparamagnetic Contrast Agents 10. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, By End User 10.1. Hospitals 10.2. Ambulatory Surgical Centers 10.3. Diagnostic Centers 11. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, By Region 11.1. North America 11.2. Latin America 11.3. Europe 11.4. East Asia 11.5. South Asia 11.6. MEA 11.7. Oceania 12. North America Market Analysis 2014 to 2021 and Forecast 2022 to 2029 13. Latin America Market Analysis 2014 to 2021 and Forecast 2022 to 2029 14. Europe Market Analysis 2014 to 2021 and Forecast 2022 to 2029 15. East Asia Market Analysis 2014 to 2021 and Forecast 2022 to 2029 16. South Asia Market Analysis 2014 to 2021 and Forecast 2022 to 2029 17. Oceania Market Analysis 2014 to 2021 and Forecast 2022 to 2029 18. Middle East and Africa Market Analysis 2014 to 2021 and Forecast 2022 to 2029 19. Emerging Countries Market Analysis 2014 to 2021 and Forecast 2022 to 2029 20. Market Structure Analysis 21. Competition Analysis 21.1. Bayer AG 21.2. GE Healthcare LLC 21.3. Guerbet GmbH 21.4. Bracco Imaging SpA 21.5. Miltenyi Biotec B.V. & Co. Kg 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Magnetic Resonance Imaging (MRI) Contrast Agents Market
